Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

15 mm margins cut NSCLC local recurrence risk after wedge resection

Increasing margin distance up to 15 mm significantly decreases the risk of local recurrence among patients undergoing wedge resection for early-stage, non-small-cell lung cancer, US researchers report.

21 Mar 2014

Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has today announced the publication of a report utilising TG1042 (ASN-002) for the treatment of Cutaneous B-Cell Lymphoma (CBCL), in the journal PLOS ONE.

21 Mar 2014

Misplaced protein provides promising drug target for kidney cancer

The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.

21 Mar 2014

Genomic analysis to study cancer in dogs can help develop new therapies for human cancers

Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof-of-concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (TGen).

19 Mar 2014

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with 95 percent accuracy.

19 Mar 2014

Archaeologists find oldest complete example of metastatic cancer in 3,000 year-old skeleton

Archaeologists have found the oldest complete example in the world of a human with metastatic cancer in a 3,000 year-old skeleton.

19 Mar 2014

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

18 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Proteomics identifies possible RCC biomarkers

Proteomic analysis has identified significant differences between the proteins expressed in renal cell carcinoma samples and in healthy renal tissue, UK researchers report.

17 Mar 2014

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Cytoplasmic expression of hypoxia inducible factor-2α is associated with poor prognosis in patients with clear cell renal cell carcinoma, study findings indicate.

17 Mar 2014

Positive margins have limited impact on RCC outcome

Positive vascular wall margins are not associated with systemic recurrence or cancer-specific survival in patients with nonmetastatic renal cell carcinoma with tumour thrombus, US research shows.

13 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Microgravity may suppress tumors, study reveals

In space, things don't always behave the way we expect them to. In the case of cancer, researchers have found that this is a good thing: some tumors seem to be much less aggressive in the microgravity environment of space compared to their behavior on Earth. This observation, reported in research published in February by the FASEB Journal, could help scientists understand the mechanism involved and develop drugs targeting tumors that don't respond to current treatments. This work is the latest in a large body of evidence on how space exploration benefits those of us on Earth.

4 Mar 2014

Researchers find unusual mutation strongly linked to rare liver cancer that affects teens

In the race for better treatments and possible cures, rare diseases are often left behind. In a collaboration of researchers at The Rockefeller University, Memorial Sloan Kettering Cancer Center and the New York Genome Center (NYGC), an unusual mutation has been found that is strongly linked to one such disease: a rare liver cancer that affects teens and young adults.

3 Mar 2014

Teen diagnosed with liver cancer explores genetic link to rare cancers

A father-daughter scientific collaboration that began after the daughter was diagnosed with a rare liver cancer has led to an important finding and could have broader implications for many other rare cancers. Their story is being published this week in a top tier journal, Science.

3 Mar 2014

Bayer HealthCare joins NORD to promote awareness of Rare Disease Day

Bayer HealthCare is joining the National Organization for Rare Disorders (NORD) and others in raising awareness of Rare Disease Day, which is being celebrated today around the world.

3 Mar 2014

NCI scientist recognized for AACR-American Cancer Society Award for Excellence in Cancer Epidemiology and Prevention

The American Association for Cancer Research (AACR) and the American Cancer Society will recognize Curtis C. Harris, M.D., with the 23rd Annual AACR-American Cancer Society Award for Excellence in Cancer Epidemiology and Prevention at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

H4 receptor activation plays part in NSCLC progression

Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows.

27 Feb 2014

Carcinoma News and Research

Further Reading

15 mm margins cut NSCLC local recurrence risk after wedge resection

Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Misplaced protein provides promising drug target for kidney cancer

Genomic analysis to study cancer in dogs can help develop new therapies for human cancers

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Archaeologists find oldest complete example of metastatic cancer in 3,000 year-old skeleton

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Proteomics identifies possible RCC biomarkers

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Positive margins have limited impact on RCC outcome

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Microgravity may suppress tumors, study reveals

Researchers find unusual mutation strongly linked to rare liver cancer that affects teens

Teen diagnosed with liver cancer explores genetic link to rare cancers

Bayer HealthCare joins NORD to promote awareness of Rare Disease Day

NCI scientist recognized for AACR-American Cancer Society Award for Excellence in Cancer Epidemiology and Prevention

H4 receptor activation plays part in NSCLC progression

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News